JPH0761940B2 - Liposomal formulation for outer skin - Google Patents
Liposomal formulation for outer skinInfo
- Publication number
- JPH0761940B2 JPH0761940B2 JP61273673A JP27367386A JPH0761940B2 JP H0761940 B2 JPH0761940 B2 JP H0761940B2 JP 61273673 A JP61273673 A JP 61273673A JP 27367386 A JP27367386 A JP 27367386A JP H0761940 B2 JPH0761940 B2 JP H0761940B2
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- present
- drug
- liposome preparation
- trichlorocarbanilide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は新規な外皮用リポソーム製剤に関する。更に詳
しくは、リン脂質を用いて製造されるリポソームにトリ
クロロカルバアニリドを含有してなる安定性、抗菌効果
の優れた外皮用リポソーム製剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a novel liposome preparation for outer coat. More specifically, the present invention relates to a liposome preparation for the outer skin, which contains trichlorocarbanilide in a liposome produced using a phospholipid and has excellent stability and antibacterial effect.
従来から、白癬菌などの真菌類およびプロピオニバクテ
リウム アクネス（Propionibacterum acnes）に代表さ
れる嫌気性ジフテロイドなどの菌類が原因および増悪因
子となる、例えば、水虫、タムシ、ニキビ、アクネ、フ
ケなどの様な疾病等があり、これらの疾病等を治療する
薬が種々開発されている。その１つとして、種々の抗菌
剤が用いられており、上記原因菌に対して効果を発揮し
ている。Traditionally, fungi such as Trichophyton and fungi such as anaerobic diphtheroids typified by Propionibacterum acnes are causes and exacerbators, such as athlete's foot, bugs, acne, acne, dandruff, etc. There are various diseases, and various drugs for treating these diseases have been developed. As one of them, various antibacterial agents have been used and are effective against the above-mentioned causative bacteria.
抗菌剤を治療薬として用いるためには、一般的には、軟
膏、水溶液、水分散液等の形態にした製剤として用いる
が、これらの抗菌剤の中には水難溶性のものが多く、使
用性が良く、安定で、薬効が十分に発揮される製剤を作
るのに多大な苦労を要していた。In order to use an antibacterial agent as a therapeutic agent, it is generally used as a preparation in the form of an ointment, an aqueous solution, an aqueous dispersion liquid, etc., but many of these antibacterial agents are poorly soluble in water It took a great deal of effort to produce a formulation that is good, stable, and fully exerts its medicinal effect.
即ち、製剤化した時に配合した薬剤が経時によって結晶
として析出する。析出を防ぐるために活性剤や油分をを
共存させて薬剤の溶解性を高めると、皮脂への薬剤の分
配が低下し、薬剤活性が十分に発揮できなくなってしま
うといった問題点が生じ、抗菌剤を使用性が良く、効果
を落とすことなく製剤に安定配合することが当業界の重
要な課題であった。That is, the drug compounded at the time of formulation is precipitated as crystals over time. When an active agent or an oil component is coexistent to prevent precipitation and the solubility of the drug is enhanced, the distribution of the drug to sebum is reduced, and the problem that the drug activity cannot be sufficiently exerted occurs It has been an important subject in the art to stably add the agent to the preparation without losing the effect.
本発明者等は上記問題点を解決すべく鋭意研究を重ねた
結果、水難溶性抗菌剤をリポソームに含有してリポソー
ム製剤を得ることにより、経時による薬剤結晶の析出が
なく、また皮脂への分配が高まり、原因菌に対する優れ
た抗菌効果を発揮することが分り、この知見に基づいて
本発明を完成するに至った。The present inventors have conducted extensive studies to solve the above-mentioned problems, and as a result, a liposome formulation containing a poorly water-soluble antibacterial agent in a liposome has been obtained to prevent precipitation of drug crystals over time and distribution to sebum. It was found that the antibacterial effect against the causative bacteria was enhanced, and the present invention was completed based on this finding.
すなわち、本発明はトリクロロカルバアニリド0.001〜2
0重量％とリン脂質0.002〜40重量％とを含有することを
特徴とする外皮用リポソーム製剤を提供するのものであ
る。That is, the present invention provides trichlorocarbanilide 0.001 to 2
The present invention provides a liposome preparation for outer skin, which contains 0% by weight and 0.002 to 40% by weight of phospholipid.
以下、本発明の構成について詳述する。Hereinafter, the configuration of the present invention will be described in detail.
本発明でいう外皮用リポソーム製剤は、リン脂質を用い
て製造されるリポソーム中にトリクロロカルバアニリド
を含有してなる外皮用リポソーム製剤である。該リポー
ソームとはリン脂質のラメラ層により形式された小胞体
であり、トリクロロカルバアニリドはリポソームを形成
するラメラ相中に含有される。また、これら抗菌剤はラ
メラ相表面に化学的および物理的に吸着されることもあ
り、本発明では上記２通りの場合と併せて「含有」と称
する。The integumental liposome preparation according to the present invention is an integumental liposome preparation in which a liposome produced using a phospholipid contains trichlorocarbanilide. The liposomes are the endoplasmic reticulum formed by the lamellar layer of phospholipids and trichlorocarbanilide is contained in the lamellar phase forming liposomes. In addition, these antibacterial agents may be chemically and physically adsorbed on the surface of the lamella phase, and in the present invention, they are collectively referred to as “containing” in the above two cases.
リポソームの調整法は、常法のいずれを用いてもよく、
例えばボルテクスィング法、ソニケーション法、プレベ
シクル法、エタノール注入法、フレンチプレス押出法、
コール酸除去法、トリトンＸ−100バッチ法、Ca2+融合
法、エーテル注入法、アニーリング法、凍結融解融合
法、W/O/Wエマルジョン法、逆相蒸発法等多くの方法が
あげられるが、これらのいずれの調整法を用いてもよ
く、これらに限定されるものではない。The liposome may be prepared by any conventional method,
For example, vortexing method, sonication method, prevesicle method, ethanol injection method, French press extrusion method,
There are many methods such as cholic acid removal method, Triton X-100 batch method, Ca 2+ fusion method, ether injection method, annealing method, freeze-thaw fusion method, W / O / W emulsion method, and reverse phase evaporation method. Any of these adjustment methods may be used, and the method is not limited to these.
本発明のリポソーム製剤の製造に用いられるリン脂質と
しては、例えば、レシチン、ケファリン、ホスファチジ
ルセリン、スフィンゴミエリン、プラスマローゲン等の
天然リン脂質、ジミリストイルレシチン、ジパルミトイ
ルレシチン、ジステアロイルレシチン、ジセチルホスフ
ェート、ステアリルアミン等の合成リン脂質、あるいは
天然由来のレシチンの不飽和炭素鎖を水素により飽和と
した水添レシチン等が挙げられる。本発明においてはこ
れらの内から任意の一種又は二種以上が選ばれて用いら
れる。Examples of the phospholipid used in the production of the liposome preparation of the present invention include natural phospholipids such as lecithin, kephalin, phosphatidylserine, sphingomyelin and plasmalogen, dimyristoyl lecithin, dipalmitoyl lecithin, distearoyl lecithin, dicetyl phosphate. , Synthetic phospholipids such as stearylamine, and hydrogenated lecithin in which unsaturated carbon chains of naturally-occurring lecithin are saturated with hydrogen. In the present invention, any one kind or two or more kinds are selected from these and used.
リポソームの分散安定性を高めるために複合脂質ラメラ
相に荷電を持たせることが望ましい。この場合、負電荷
を持たせるときは上記のホスファチジルセリン、ジセチ
ルホスフェートなどの負電荷を持つ脂質を、正電荷を持
たせるときは上記のステアリルアミンなどの正電荷を持
つ脂質を用いればよい。It is desirable to charge the complex lipid lamellar phase in order to enhance the dispersion stability of the liposome. In this case, a lipid having a negative charge such as phosphatidylserine or dicetyl phosphate may be used to give a negative charge, and a lipid having a positive charge such as stearylamine may be used to give a positive charge.
本発明のリポソーム製剤の安定化のために、さらにリポ
ソーム中にステロールを配合することができる。かかる
ステロールとしては、例えばコレステロール、β−フィ
トステロール、スチグマステロール、カンペステロール
または植物材料から抽出されるステロールの混合物等が
挙げられる。To stabilize the liposome preparation of the present invention, a sterol can be further incorporated into the liposome. Examples of such sterols include cholesterol, β-phytosterol, stigmasterol, campesterol, or a mixture of sterols extracted from plant materials.
本発明で用いられるトリクロロカルバアニリドは、3,4,
4′トリクロロカルバアニリドが好ましい。The trichlorocarbanilide used in the present invention is 3,4,
4'Trichlorocarbanilide is preferred.
リポソーム製剤中のトリクロロカルバアニリドの配合量
は製剤全量中の0.001〜20重量％配合することが望まし
い。また、概当量の薬剤をリポソームに安定包埋させる
ためには、薬剤の量が、複合脂質と薬剤混合中の薬剤量
として0.002〜40重量％を占めるのが好ましいが、さら
に好ましくは５％以下であることが望ましい。The content of trichlorocarbanilide in the liposome preparation is preferably 0.001 to 20% by weight based on the total weight of the preparation. Further, in order to stably embed an approximately equivalent amount of the drug in the liposome, it is preferable that the amount of the drug accounts for 0.002 to 40% by weight as the amount of the drug mixed with the complex lipid, but more preferably 5% or less. Is desirable.
また、リポソーム製剤安定化のために、必要に応じてさ
らに配合されるステロールの配合量は、上限50％までで
好ましくは0.001〜30重量％である。Further, for stabilizing the liposome preparation, the compounding amount of sterol which is further compounded as necessary is up to 50% and preferably 0.001 to 30% by weight.
本発明のリポソーム製剤はリポソームの形態を破壊しな
い成分であれば、通常の医薬品、化粧品（医薬部外品を
含む）等に配合される一般的な成分を配合できる。The liposome preparation of the present invention may be a general component that is commonly used in ordinary medicines, cosmetics (including quasi drugs), etc., as long as it does not destroy the morphology of liposomes.
本発明のリポソーム製剤は、経時で安定であり、これを
皮膚表面に塗布することにより、リポソーム自体は経皮
吸収されることはないが、薬剤の皮脂への分配を高め局
所における薬剤濃度の増大をもたらし充分な効果が発揮
される。The liposome preparation of the present invention is stable over time, and by applying this on the skin surface, the liposome itself is not percutaneously absorbed, but it enhances distribution of the drug to sebum and increases the drug concentration locally. Is brought to full effect.
本発明により、より少ない薬剤量で従来と同様の効果が
期待できる。また、リポソーム製剤自身の安全性も高
い。According to the present invention, the same effect can be expected with a smaller amount of drug. In addition, the safety of the liposome preparation itself is high.
次に本発明の一層の理解のために、実施例をあげて更に
詳細に説明するが本発明をこれらの実施例によって限定
するものではないことはいうまでもない。Next, for further understanding of the present invention, the present invention will be described in more detail with reference to Examples, but it goes without saying that the present invention is not limited to these Examples.
実施例１ 50mlナス型フラスコ中でジパルミトイルレシチン0.63
g、コレステロール0.32g、ジセチルホスフェート50mgお
よび3,4,4′トリクロロカルバアニリド10mgをクロロホ
ルム10mlに溶解した後、ロータリーエバポレーターを用
いてクロロホルムを留去し、フラスコ底壁に複合脂質膜
を得た。これを真空デシケータ中で２時間乾燥しクロロ
ホルムを完全に留去した。これにリン酸緩衝液（PH7.
4）10mlを加え、50℃で30分水和させた後、ボルテック
スミキサーにより激しく振とうすることによりフラスコ
底壁に形成した上記複合脂質膜を完全に分散せしめて粒
径0.1〜数μｍのリポソームを形成させ、リポソーム分
散液とした。Example 1 Dipalmitoyl lecithin 0.63 in a 50 ml eggplant-shaped flask
g, cholesterol 0.32 g, dicetyl phosphate 50 mg and 3,4,4 'trichlorocarbanilide 10 mg were dissolved in chloroform 10 ml, and then chloroform was distilled off using a rotary evaporator to obtain a complex lipid membrane on the bottom wall of the flask. . This was dried in a vacuum desiccator for 2 hours to completely remove chloroform. To this, phosphate buffer (PH7.
4) After adding 10 ml and hydrating at 50 ° C. for 30 minutes, shake the mixture vigorously with a vortex mixer to completely disperse the above-mentioned complex lipid membrane formed on the bottom wall of the flask to obtain liposomes having a particle size of 0.1 to several μm. To form a liposome dispersion liquid.
実施例２ 実施例１に準じて、後述表１に示す各濃度の3,4,4′ト
リクロロカルバアニリドを含有するリポソーム製剤を得
た。また、リン脂質としてジパルミトイルレシチンに替
えて、水添レシチンを含有したリポソーム製剤を得た。Example 2 According to Example 1, a liposome preparation containing each concentration of 3,4,4 ′ trichlorocarbanilide shown in Table 1 below was obtained. In addition, a liposome preparation containing hydrogenated lecithin was obtained instead of dipalmitoyl lecithin as the phospholipid.
比較例１ 実施例２の同濃度の3,4,4′トリクロロカルバアニリド
のエタノール溶液を得た。Comparative Example 1 An ethanol solution of 3,4,4 ′ trichlorocarbanilide having the same concentration as in Example 2 was obtained.
実施例３で得たリポソーム製剤と、比較例１のエタノー
ル溶液との抗菌効果をペーパーディスク法により評価し
た。The antibacterial effect of the liposome preparation obtained in Example 3 and the ethanol solution of Comparative Example 1 was evaluated by the paper disk method.
即ち、あらかじめスタフィロコッカス アウレウス（St
aphylococcus aureus）FDA209P株10S/ml程度均一に分散
させた肉汁寒天培地に皮膚表面をモデル化するために皮
膚表面の皮脂量に相当する皮脂類似油分のエマルジョン
を混入させた培地を重層固化させる。リポソーム製剤お
よびエタノール溶液100μをしみこませた直径8mmのト
ーヨーろ紙を、上記培地の上部に接触させ、30℃24時間
培養する。抗菌剤が有効に作用している範囲は菌の増殖
が阻止される。この阻止帯の直径から抗菌効果を評価し
た。That is, Staphylococcus aureus (St
aphylococcus aureus) FDA209P strain 10 S / ml About 10 S / ml of homogenized agar broth agar medium is mixed with an emulsion of oil similar to sebum on the surface of the skin in order to model the surface of the skin, and then solidified. A Toyo filter paper with a diameter of 8 mm impregnated with the liposome preparation and 100 μm of an ethanol solution is brought into contact with the upper part of the above medium, and cultured at 30 ° C. for 24 hours. In the area where the antibacterial agent is effectively acting, the growth of bacteria is blocked. The antibacterial effect was evaluated from the diameter of this inhibition zone.
表１から明らかなように、本発明によるリポソーム製剤
は、エタノール溶液による薬剤単独塗布より強い抗菌作
用を示し優れた剤型であることが分る。 As is clear from Table 1, the liposome preparation according to the present invention exhibits a stronger antibacterial action than the drug alone application with an ethanol solution and is an excellent dosage form.
実施例４ 50mlナス型フラスコ中で水添レシチン2.8g、コレステロ
ール1.2gおよび3,4,4′トリクロロカルバアニリド40mg
をクロロホルム20mlに溶解した後ロータリーエバポレー
ターを用いてクロロホルムを留去し、フラスコ底壁に複
合脂質膜を得た。これを真空デシケータ中で２時間乾燥
しクロロホルムを完全に留去した。これに、イオン交換
水13.96gを加え、60℃に加熱しホモミキサーにより複合
脂質膜を完全に分散せしめてリポソームを形成させた。
この分散液にさらに1,3−ブチレングリコール2gを加え
た後１％ヒアルロン酸水溶液で後述表２に示す各濃度に
希釈してリポソーム分散ゲル製剤を得た。Example 4 Hydrogenated lecithin 2.8 g, cholesterol 1.2 g and 3,4,4'-trichlorocarbanilide 40 mg in a 50 ml eggplant-shaped flask.
Was dissolved in 20 ml of chloroform and then chloroform was distilled off using a rotary evaporator to obtain a complex lipid membrane on the bottom wall of the flask. This was dried in a vacuum desiccator for 2 hours to completely remove chloroform. To this, 13.96 g of ion-exchanged water was added, heated to 60 ° C., and the complex lipid membrane was completely dispersed with a homomixer to form liposomes.
To this dispersion, 2 g of 1,3-butylene glycol was further added, and then diluted with a 1% aqueous solution of hyaluronic acid to each concentration shown in Table 2 below to obtain a liposome-dispersed gel preparation.
上記溶液にスタフィロコッカス アウレウス（Staphylo
coccas aureus）FDA209P株を105/ml接種しその殺菌力を
溶液1ml中の菌数変化から評価した。To the above solution, Staphylococcus aureus
Coccas aureus) FDA209P strain was inoculated at 10 5 / ml, and its bactericidal activity was evaluated from the change in the number of bacteria in 1 ml of the solution.
表２から明らかなように、本発明によるリポソーム製剤
は、ゲル製剤にして薬剤0.01％という低濃度で十分に殺
菌能を有することが分る。 As is clear from Table 2, the liposome preparation according to the present invention has a sufficient bactericidal activity at a drug concentration as low as 0.01% as a gel preparation.
Claims (1)
％とリン脂質0.002〜40重量％とを含有することを特徴
とする外皮用リポソーム製剤。1. A liposome preparation for the outer skin, which comprises 0.001 to 20% by weight of trichlorocarbanilide and 0.002 to 40% by weight of phospholipid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61273673A JPH0761940B2 (en) | 1986-11-17 | 1986-11-17 | Liposomal formulation for outer skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61273673A JPH0761940B2 (en) | 1986-11-17 | 1986-11-17 | Liposomal formulation for outer skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63126820A JPS63126820A (en) | 1988-05-30 |
| JPH0761940B2 true JPH0761940B2 (en) | 1995-07-05 |
Family
ID=17530949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61273673A Expired - Lifetime JPH0761940B2 (en) | 1986-11-17 | 1986-11-17 | Liposomal formulation for outer skin |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0761940B2 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2661331A1 (en) * | 1990-04-30 | 1991-10-31 | Oreal | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION CONTAINING VESICLES FORMED BY A MIXTURE OF PHOSPHOLIPIDS / GLYCOLIPIDS. |
| DE69230235T2 (en) * | 1991-04-08 | 2000-05-31 | Kao Corp., Tokio/Tokyo | Cosmetic composition |
| GB9111611D0 (en) * | 1991-05-30 | 1991-07-24 | Sandoz Ltd | Liposomes |
| DE4306475A1 (en) * | 1993-03-02 | 1994-09-08 | Ensenat Pedro Gonzalez | Liposomes containing chlorhexidine diacetate or chlorhexidine digluconate |
| DE9312509U1 (en) * | 1993-08-20 | 1993-10-28 | Euro-Celtique S.A., Luxemburg/Luxembourg | Preparations for external administration of antiseptic and / or wound healing promoting agents |
| US5863556A (en) * | 1993-08-20 | 1999-01-26 | Euro-Celtique, S.A. | Preparations for the external application of antiseptic agents and/or agents promoting the healing of wounds |
| AU6793598A (en) * | 1997-03-31 | 1998-10-22 | University Of Iowa Research Foundation, The | Glycosylceramide-containing liposomes |
| EP1043016B1 (en) * | 1999-03-30 | 2014-08-20 | Sodic Sa | A plant extract based on glycerides,phospholipids and phytosphingolipids, a method for the preparation of this extract and a cosmetic composition containing the same |
| US7297344B1 (en) | 1999-05-27 | 2007-11-20 | Euro-Celtique, S.A. | Preparations for the promotion of wound healing in the upper respiratory tract and/or ear |
| US7300667B1 (en) | 1999-05-27 | 2007-11-27 | Euro-Celtique, S.A. | Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract |
| ATE340561T1 (en) | 1999-05-27 | 2006-10-15 | Euro Celtique Sa | USE OF ANTISEPTICS FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE PROPHYLAXIS AND TREATMENT OF INFLAMMATION INSIDE THE HUMAN BODY |
| US20020115624A1 (en) * | 2000-06-22 | 2002-08-22 | Behar Samuel M. | Alpha gylcosylceramides for treating bacterial and fungal infections |
| DE102005063375A1 (en) * | 2005-09-15 | 2007-04-19 | Schülke & Mayr GmbH | Antimicrobial preparations containing octenidine dihydrochloride encapsulated in liposomes |
| JP2011051966A (en) * | 2009-09-03 | 2011-03-17 | Daiya Seiyaku Kk | Plaster for use in treatment of tinea unguium |
| JP6471407B2 (en) * | 2013-12-25 | 2019-02-20 | サンスター株式会社 | Oral or throat composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4891208A (en) * | 1985-04-10 | 1990-01-02 | The Liposome Company, Inc. | Steroidal liposomes |
| CA1260393A (en) * | 1984-10-16 | 1989-09-26 | Lajos Tarcsay | Liposomes of synthetic lipids |
| JPH0832623B2 (en) * | 1985-04-10 | 1996-03-29 | ザ リポソ−ム カンパニ−、インコ−ポレ−テッド | Steroid liposome |
| AU598002B2 (en) * | 1986-07-15 | 1990-06-14 | Cilag Ltd. | Method of preparing single bilayered liposomes |
-
1986
- 1986-11-17 JP JP61273673A patent/JPH0761940B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPS63126820A (en) | 1988-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5618840A (en) | Antibacterial oil-in-water emulsions | |
| US5549901A (en) | Antimicrobial oil-in-water emulsions | |
| US8182835B2 (en) | Sustained-release liposomal anesthetic compositions | |
| CA1339008C (en) | Amphotericin b liposome preparation | |
| US5547677A (en) | Antimicrobial oil-in-water emulsions | |
| AU673023B2 (en) | Cosmetic delivery system for salicylic acid and process for preparation of the same | |
| JPH0761940B2 (en) | Liposomal formulation for outer skin | |
| US8241648B2 (en) | Amphiphilic or lipophilic polar functionalized fullerenes and their uses | |
| DE60318227T2 (en) | AGGREGATES WITH INCREASED DEFORMABILITY, CONSISTING OF AT LEAST THREE AMPHIPHILES, FOR IMPROVED TRANSPORT BY PIVOTABLE BARRIERS AND FOR NON-INVERSIVE ADMINISTRATION OF VIVO MEDICAMENTS, IN PARTICULAR THROUGH THE SKIN | |
| US5741515A (en) | Ketoprofen liposomes | |
| DE19810655A1 (en) | Pharmaceutical composition containing cyclosporin A suitable for topical administration for treating disorders of skin, mucosa and eyes | |
| CA2393487C (en) | Pharmaceutical preparation for the treatment of oncoses | |
| RU2665946C2 (en) | Composition containing onion extract and liposomes | |
| EP0525655B1 (en) | Formulations useful for vaginal dryness treatment | |
| JPH07501825A (en) | Amphotericin B composition with enhanced antifungal activity | |
| JPH11504946A (en) | Anti-glucocorticoid drug | |
| RU2217128C1 (en) | Preparation for topical application in treatment of pulmonary tuberculosis and suppurative-inflammatory diseases | |
| WO2001072289A2 (en) | Medicament for the stimulation of leucopoiesis and treatment of tumour and protozoan diseases acarinosis and arthropod-borne diseases and a method for production thereof | |
| IE920400A1 (en) | Pharmaceutical product for the treatment of virus diseases | |
| US20040175417A1 (en) | Amphotericin B liposome preparation | |
| IE920401A1 (en) | Pharmaceutical product for the treatment of virus diseases | |
| JPH0377822A (en) | Liposome preparation | |
| JPH0211515A (en) | Pharmaceutical preparation containing ferbinac |